ERBB2 and breast carcinoma: With the implementation of new HER2-targeting therapies for breast cancer [40] and the emergence of trials investigating the antibody drug conjugate trastuzumab deruxtecan targeting HER2-low EBC [41], similar analyses to those in the present study should be conducted to evaluate potential effects of new HER2 therapies on micrometastases and their impact on survival.